Agonists
- Mirabegron (YM-178), approved for treatment of overactive bladder in Japan and the United States.
- Amibegron (SR-58611A)
- Solabegron (GW-427,353)
- L-796,568
- CL-316,243
- LY-368,842
- Ro40-2148
A selective β3 agonist has potential weight loss effects through modulation of lipolysis.
Read more about this topic: Beta-3 Adrenergic Receptor